Biophytis

Biophytis Total Assets

The Total Assets of Biophytis (ALBPS.PA) as of Nov 19, 2026 is 6.90 M EUR. In the previous year, Total Assets was 11.96 M EUR — a change of -42.29% (lower).

Total Assets

6.90 MEUR

YoY

-42.29%

Last updated:

Total Assets of Biophytis is 2024 6.90 M EUR. Total Assets of Biophytis was 2023 11.96 M EUR. It decreases by -42.29% lower compared to the previous year.

The Biophytis Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2017
25.95 M EUR
Jan 1, 2018
21.86 M EUR
Jan 1, 2019
17.67 M EUR
Jan 1, 2020
27.21 M EUR
Jan 1, 2021
36.26 M EUR
Jan 1, 2022
21.99 M EUR
Jan 1, 2023
11.96 M EUR
Jan 1, 2024
6.90 M EUR
The Biophytis Total Assets history
YEARTotal AssetsYoY
6.90 MEUR-42.29%
11.96 MEUR-45.60%
21.99 MEUR-39.37%
36.26 MEUR+33.27%
27.21 MEUR+53.97%
17.67 MEUR-19.17%
21.86 MEUR-15.74%
25.95 MEUR+209.15%
8.39 MEUR-37.91%
13.52 MEUR+3,393.95%
386,856.00EUR—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Biophytis Stock analysis

What does Biophytis do? Biophytis SA develops therapeutics for sarcopenia and Age Related Macular Degeneration, focusing on restoring muscular and visual functions. The company's clinical programs include Sarconeos (BIO101) for sarcopenia and Macuneos (BIO201) for ARMD, developed simultaneously in the U.S. and domestic markets. Biophytis generates revenue through clinical development partnerships and potential future product sales, targeting pharmaceutical companies and healthcare providers seeking treatments for aging-related conditions. The company's primary products are Sarconeos (BIO101) and Macuneos (BIO201), with clinical development ongoing for both. Biophytis targets healthcare providers and pharmaceutical companies as key buyers, particularly those focused on aging diseases. The firm's strategy involves advancing drug candidates through clinical trials to secure regulatory approvals and commercial partnerships. Biophytis SA's business model centers on the development of two drug candidates, Sarconeos (BIO101) and Macuneos (BIO201), for sarcopenia and ARMD respectively. The company's revenue streams are derived from clinical development collaborations and potential future licensing agreements with pharmaceutical firms. The target market comprises healthcare institutions and pharmaceutical companies seeking innovative treatments for age-related medical conditions. Biophytis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Biophytis stock

Total Assets of Biophytis is 6.90 M EUR in 2024.

Total Assets of Biophytis changed from 11.96 M EUR to 6.90 M EUR, representing a -42.29% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets Biophytis since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's Biophytis historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Biophytis

All Key Metrics — Biophytis